You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新華製藥(000756.SZ)半年度淨利潤升19.54%至1.47億元
格隆匯 08-19 16:59

格隆匯8月19日丨新華製藥(000756.SZ)發佈2019年半年度報告,實現營業收入31億元,同比增長15.34%;歸屬於上市公司股東的淨利潤1.47億元,同比增長19.54%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.36億元,同比增長12.97%;基本每股收益0.24元。

狠抓製劑營銷,重點培育戰略新品種,上半年十大戰略品種銷售收入同比增長33.6%,其中舒泰得(雷貝拉唑鈉片)銷售收入同比增長22.07%,佳和洛(格列美脲片)銷售收入同比增長27.33%

積極開拓跨境業務,佈局新零售業務,上半年電子商務實現銷售收入同比增長29.68%

上半年公司鹽酸法舒地爾及其注射液通過國家藥監局技術審評,取得新藥註冊批件。獲得1個新藥臨牀批件,獲得了6個獸藥批准文號。

兩個規格格列美脲片通過了一致性評價,10個產品申報資料已遞交國家藥審中心並等待批准,標誌着本公司一致性評價工作開始進入收穫期。

基於產業化關鍵技術的咖啡因綠色製備體系構建與規模開發榮獲2018年度山東省科學技術進步二等獎。上半年獲得專利授權10件。公司被公示為山東省技術創新示範企業,被評為山東人才工作先進單位。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account